Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04864795 · ClinicalTrials.gov registry record

Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

A clinical trial, sponsored by Vifor (International).

Completed
Registry status
2,636
Enrollment target

NCT04864795: Completed study, sponsored by Vifor (International).

NCT04864795 is a clinical trial that has completed, run by Vifor (International). The registered enrollment target is 2,636 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04864795 has completed, sponsored by Vifor (International).

COMPLETED
Registry status
2,636 participants
Enrollment target

Study Summary

The CARE-HK in HF is a registry study based on the hypothesis that adherence to guidelines is associated with improved real-world outcomes for heart failure (HF) patients. For the purpose of this study, adherence to guidelines is defined as adherence to RAASi treatment recommendations, according to the AHA/ACC and ESC guidelines. Objectives relating to patiromer effectiveness will only be evaluated if a sufficient number of patients are available. The study aims to evaluate in patients at high risk of hyperkalaemia; patients treated with ACEi/ARB/ARNi, and either treated with or candidates for treatment with MRA.

Primary Outcome

overall

Trial Details

FieldValue
Enrollment Target 2,636 participants
Start Date 2021-04-19
Est. Completion 2024-08-30
Vifor (International)

2 total trials

What the finished NCT04864795 record still lists

NCT04864795 is an observational study that tracks outcomes without assigning an intervention. Its 2,636 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT04864795 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04864795 about?

NCT04864795 is a clinical study titled "Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia". The CARE-HK in HF is a registry study based on the hypothesis that adherence to guidelines is associated with improved real-world outcomes for heart failure (HF) patients. For the purpose of this study, adherence to guidelines is defined as adherence to RAASi treatment recommendations, according to ...

What is the current status of trial NCT04864795?

This trial is currently completed. The enrollment target is 2,636 participants. The study started on 2021-04-19. Estimated completion is 2024-08-30.

Who is sponsoring clinical trial NCT04864795?

This trial is sponsored by Vifor (International), which has 2 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06455085 · 2,634 participants · NA

    RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

  • NCT06825715 · 2,653 participants · NA

    Multilevel Intervention for Precision Oncology

  • NCT06033950 · 2,600 participants · Phase 3

    A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists

  • NCT06574672 · 2,600 participants · NA

    Embedded Palliative Care in the MICU

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04864795, the US trial registry maintained by the National Library of Medicine. NCT04864795 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.